Further CYP-001 GvHD Clinical Data Published in Nature Medicine
Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60% MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to an...
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
MELBOURNE, Australia, April 8, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK...
First Patient Treated in Phase 2 GvHD Trial
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical...
LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation
Key Highlights: * Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant * Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost t...
US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
Key Highlights: * US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company * Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of ne...
Cynata Enters into a New Strategic Partnership with Fujifilm
Key highlights * Cynata and Fujifilm have entered into a new strategic partnership which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus™ therapeutic mesenchymal stem cell (MSC) products * Cyn...
